Theranostic markers for personalized therapy of spider phobia: Methods of a bicentric external cross-validation machine learning approach.


Journal

International journal of methods in psychiatric research
ISSN: 1557-0657
Titre abrégé: Int J Methods Psychiatr Res
Pays: United States
ID NLM: 9111433

Informations de publication

Date de publication:
06 2020
Historique:
received: 09 05 2019
revised: 18 09 2019
accepted: 08 10 2019
pubmed: 10 12 2019
medline: 29 6 2021
entrez: 10 12 2019
Statut: ppublish

Résumé

Embedded in the Collaborative Research Center "Fear, Anxiety, Anxiety Disorders" (CRC-TRR58), this bicentric clinical study aims at identifying biobehavioral markers of treatment (non-)response by applying machine learning methodology with an external cross-validation protocol. We hypothesize that a priori prediction of treatment (non-)response is possible in a second, independent sample based on multimodal markers. One-session virtual reality exposure treatment (VRET) with patients with spider phobia was conducted on two sites. Clinical, neuroimaging, and genetic data were assessed at baseline, post-treatment and after 6 months. The primary and secondary outcomes defining treatment response are as follows: 30% reduction regarding the individual score in the Spider Phobia Questionnaire and 50% reduction regarding the individual distance in the behavioral avoidance test. N = 204 patients have been included (n = 100 in Würzburg, n = 104 in Münster). Sample characteristics for both sites are comparable. This study will offer cross-validated theranostic markers for predicting the individual success of exposure-based therapy. Findings will support clinical decision-making on personalized therapy, bridge the gap between basic and clinical research, and bring stratified therapy into reach. The study is registered at ClinicalTrials.gov (ID: NCT03208400).

Identifiants

pubmed: 31814209
doi: 10.1002/mpr.1812
pmc: PMC7301283
doi:

Substances chimiques

Biomarkers 0

Banques de données

ClinicalTrials.gov
['NCT03208400']

Types de publication

Clinical Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1812

Informations de copyright

© 2019 The Authors. International Journal of Methods in Psychiatric Research Published by John Wiley & Sons Ltd.

Références

Nat Neurosci. 2017 Feb 23;20(3):365-377
pubmed: 28230847
Mol Psychiatry. 2014 Jan;19(1):122-8
pubmed: 23319006
Eur J Oral Sci. 2009 Jun;117(3):279-85
pubmed: 19583756
Hum Brain Mapp. 2014 Jul;35(7):2995-3007
pubmed: 24038516
Cyberpsychol Behav. 2007 Oct;10(5):722-4
pubmed: 17927544
Acta Psychiatr Scand. 1990 Jul;82(1):77-81
pubmed: 2399824
Brain Stimul. 2017 Mar - Apr;10(2):291-297
pubmed: 27931887
JAMA Psychiatry. 2014 Jun;71(6):706-15
pubmed: 24789675
Eur Neuropsychopharmacol. 2017 Apr;27(4):360-371
pubmed: 28233670
Neuroinformatics. 2014 Jul;12(3):471-86
pubmed: 24676797
Cyberpsychol Behav. 2001 Jun;4(3):335-9
pubmed: 11710257
Psychother Psychosom Med Psychol. 2010 Nov;60(11):442-50
pubmed: 20200804
Clin Psychol Rev. 2015 Dec;42:72-82
pubmed: 26319194
J Consult Clin Psychol. 2011 Jun;79(3):406-20
pubmed: 21534651
Front Psychiatry. 2017 Jun 09;8:99
pubmed: 28649205
J Behav Ther Exp Psychiatry. 1996 Sep;27(3):241-4
pubmed: 8959425
Neurosci Biobehav Rev. 2018 Dec;95:61-72
pubmed: 30278195
Curr Psychiatry Rep. 2017 Jul;19(7):42
pubmed: 28540594
Cogn Behav Ther. 2009;38(2):114-20
pubmed: 20183690
Nat Rev Neurosci. 2007 Sep;8(9):725-32
pubmed: 17704814
Behav Res Ther. 1996 Sep;34(9):707-15
pubmed: 8936753
JAMA Psychiatry. 2016 Jun 1;73(6):557-64
pubmed: 27145449
Biol Mood Anxiety Disord. 2013 Feb 07;3(1):4
pubmed: 23388219
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Apr 20;91:60-71
pubmed: 29627509
Depress Anxiety. 2015 Sep;32(9):656-63
pubmed: 26115440
Mol Psychiatry. 2016 May;21(5):680-5
pubmed: 26260493
Depress Anxiety. 2012 Feb;29(2):85-93
pubmed: 22065564
Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):619-628
pubmed: 19777560
J Anxiety Disord. 2016 Dec;44:92-101
pubmed: 27842240
JAMA. 2016 Feb 9;315(6):551-2
pubmed: 26864406
Cogn Behav Ther. 2013;42(4):284-91
pubmed: 24245707
Curr Opin Psychiatry. 2016 Jan;29(1):25-31
pubmed: 26651007
Neuropsychopharmacology. 2011 Aug;36(9):1879-85
pubmed: 21525857
Nat Neurosci. 2015 Dec;18(12):1811-8
pubmed: 26571459
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
J Anxiety Disord. 2012 Jun;26(5):583-9
pubmed: 22440391
JAMA Psychiatry. 2014 Nov;71(11):1222-30
pubmed: 25188810
Neuroimage. 2002 Sep;17(1):317-23
pubmed: 12482086
Behav Res Ther. 1997 Nov;35(11):987-96
pubmed: 9431728
J Affect Disord. 2013 May;147(1-3):180-5
pubmed: 23218248
Cognit Ther Res. 2012 Oct 1;36(5):427-440
pubmed: 23459093
Behav Res Ther. 2002 Sep;40(9):983-93
pubmed: 12296495
Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79
pubmed: 21896369
Nature. 2014 Jul 17;511(7509):287-9
pubmed: 25030152
Neuropsychopharmacology. 2015 May;40(6):1528-38
pubmed: 25563749
Behav Res Ther. 2014 Nov;62:120-8
pubmed: 25156399
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Apr 20;91:113-121
pubmed: 30290208
Neurosci Biobehav Rev. 2016 Jul;66:143-62
pubmed: 27168345
Nervenarzt. 2002 Mar;73(3):262-71
pubmed: 11963262
Neuropsychopharmacology. 2014 Apr;39(5):1254-61
pubmed: 24270731
Eur Arch Psychiatry Clin Neurosci. 2013 Mar;263(2):119-31
pubmed: 22639242
Neurosci Biobehav Rev. 2012 Apr;36(4):1140-52
pubmed: 22305994
JAMA Psychiatry. 2015 Jan;72(1):68-74
pubmed: 25409415
Transl Psychiatry. 2017 Aug 29;7(8):e1219
pubmed: 28850109
Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):16033-8
pubmed: 17032778
Mol Psychiatry. 2017 Jan;22(1):37-43
pubmed: 27843153
PLoS One. 2013 Sep 11;8(9):e74657
pubmed: 24040309
Depress Anxiety. 2018 Jun;35(6):502-514
pubmed: 29451967
J Consult Clin Psychol. 2015 Dec;83(6):1108-22
pubmed: 26302248
JAMA Psychiatry. 2013 Jan;70(1):87-97
pubmed: 22945462
Int J Methods Psychiatr Res. 2020 Jun;29(2):e1812
pubmed: 31814209
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Mar;3(3):223-230
pubmed: 29486863
Transl Psychiatry. 2015 Mar 17;5:e530
pubmed: 25781229
Hum Brain Mapp. 2014 Nov;35(11):5356-67
pubmed: 24862560
Mol Psychiatry. 2016 Jun;21(6):813-22
pubmed: 26324098
Clin Psychol Rev. 2008 Jul;28(6):1021-37
pubmed: 18410984

Auteurs

Hanna Schwarzmeier (H)

Department of Psychiatry, Psychosomatics, and Psychotherapy, Center for Mental Health, University Hospital of Würzburg, Würzburg, Germany.

Elisabeth Johanna Leehr (EJ)

Department of Psychiatry and Psychotherapy, University of Münster, Münster, Germany.

Joscha Böhnlein (J)

Department of Psychiatry and Psychotherapy, University of Münster, Münster, Germany.

Fabian Reinhard Seeger (FR)

Department of Psychiatry, Psychosomatics, and Psychotherapy, Center for Mental Health, University Hospital of Würzburg, Würzburg, Germany.

Kati Roesmann (K)

Institute for Biomagnetism and Biosignalanalysis, University of Münster, Münster, Germany.
Otto-Creutzfeld Center for Cognitive and Behavioral Neuroscience, University of Münster, Münster, Germany.

Bettina Gathmann (B)

Institute of Medical Psychology and Systems Neuroscience, University of Münster, Münster, Germany.

Martin J Herrmann (MJ)

Department of Psychiatry, Psychosomatics, and Psychotherapy, Center for Mental Health, University Hospital of Würzburg, Würzburg, Germany.

Niklas Siminski (N)

Department of Psychiatry, Psychosomatics, and Psychotherapy, Center for Mental Health, University Hospital of Würzburg, Würzburg, Germany.

Markus Junghöfer (M)

Institute for Biomagnetism and Biosignalanalysis, University of Münster, Münster, Germany.
Otto-Creutzfeld Center for Cognitive and Behavioral Neuroscience, University of Münster, Münster, Germany.

Thomas Straube (T)

Institute of Medical Psychology and Systems Neuroscience, University of Münster, Münster, Germany.
Otto-Creutzfeld Center for Cognitive and Behavioral Neuroscience, University of Münster, Münster, Germany.

Dominik Grotegerd (D)

Department of Psychiatry and Psychotherapy, University of Münster, Münster, Germany.

Udo Dannlowski (U)

Department of Psychiatry and Psychotherapy, University of Münster, Münster, Germany.
Otto-Creutzfeld Center for Cognitive and Behavioral Neuroscience, University of Münster, Münster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH